Category Archives: TRIPS flexibilities

The expanding universe of IP

Source: The Hindu Granting data exclusivity for clinical trials would undermine access to medicines April 26 is World Intellectual Property (IP) day. Over the years, global IP standards have steadily expanded beyond World Trade Organisation (WTO) requirements, thanks to free … Continue reading

Posted in Data Exclusivity, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Eli Lilly’s ISDS Patent Claim against Canada Defeated

In an unprecedented case, Eli Lilly initiated an amended investor-state-dispute-settlement (ISDS) claim against the government of Canada in 2013 after Canada’s highest courts upheld invalidations on new therapeutic use patents for two chemical compounds – olanzapine and atomoxetine, the active … Continue reading

Posted in Compulsory Licensing, FTA, Investor state dispute, Uncategorized | Leave a comment

Avoid Patent Clauses in Trade Treaties that can Kill Millions

By Martin Khor, Inter Press Service | February 27, 2017 PENANG, Feb 27 2017 (IPS) – Recently a very interesting article on why there are inequalities in access to health care and how  medicine prices are beyond the reach of many … Continue reading

Posted in Data Exclusivity, FTA, Patent Term Extension, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

RCEP and Health: This Kind of ‘Progress’ is Not What India and the World Need

Source: The Wire Concerns remain over the impact of RCEP negotiations on public health and access to medicines Negotiators from 16 countries are meeting in Kobe, Japan on Monday to begin the 17th round of negotiations of the Regional Comprehensive Economic … Continue reading

Posted in Data Exclusivity, Investor state dispute, IPR, Patent, Patent Term Extension, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Compulsory licensing required for essential drugs: Y K Hamied

Pragmatic compulsory licensing policy is needed to enable India to look after health of its people as it cannot afford monopoly in healthcare with the challenges it faces, Cipla’s Y K Hamied said.

Posted in Compulsory Licensing, Uncategorized | Leave a comment

European Commission publishes negotiating proposals for EU-Indonesia trade deal

It is important to note that the EU proposals on IP are TRIPS-plus in multiple regards and would surely reduce policy space in Indonesia and negatively impact access to affordable medicines.  Even a preliminary review of the proposal reveals: A … Continue reading

Posted in IPR Enforcement, Patent Term Extension, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

How charity is fuelling a superbug in India?

By Ruhi Khandar, The Ken The evil superbug is on the lookout for new hosts. The hero has the weapon, he can conquer it, but only if he is willing. The superbug is antibiotic-resistant bacteria, which causes multi-drug-resistant tuberculosis (MDR-TB), the … Continue reading

Posted in Compulsory Licensing, Drugs, Tuberculosis (TB), Uncategorized | Tagged , , | Leave a comment